Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20599988 | 0.88 | GRM5 (0.79) | GRM5CYP3A4 | |
| SCHEMBL20600031 | 0.88 | GRM5 (0.73) | GRM5 | |
| SCHEMBL20600068 | 0.88 | GRM5 (0.70) | GRM5CYP3A4 | |
| SCHEMBL22613691 | 0.88 | GRM5 (0.79) | GRM5CYP3A4 | |
| SCHEMBL20599948 | 0.87 | GRM5 (0.61) | GRM5 | |
| SCHEMBL20599941 | 0.87 | GRM5 (0.76) | GRM5 | |
| SCHEMBL22619537 | 0.87 | GRM5 (0.79) | GRM5CYP3A4 | |
| SCHEMBL29915396 | 0.87 | GRM5 (0.79) | GRM5CYP3A4 | |
| SCHEMBL20599925 | 0.86 | GRM5 (0.78) | GRM5 | |
| SCHEMBL20599994 | 0.85 | GRM5 (0.72) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200347078-A1 | HETEROCYCLYLMETHYLIDENE DERIVATIVES AND THEIR USE AS MODULATORS OF mGluR5 RECEPTORS | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A. (IT) | 2020-11-05 | — | — | US | claimed |
| EP-3645521-A1 | HETEROCYCLYLMETHYLIDENE DERIVATIVES AND THEIR USE AS MODULATORS OF mGluR5 RECEPTORS | Recordati Industria Chimica E Farmaceutica SPA (IT) | 2020-05-06 | — | — | EP | claimed |
| WO-2019002571-A1 | HETEROCYCLYLMETHYLIDENE DERIVATIVES AND THEIR USE AS MODULATORS OF mGluR5 RECEPTORS | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2019-01-03 | — | — | WO | claimed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| US-20200347078-A1 | HETEROCYCLYLMETHYLIDENE DERIVATIVES AND THEIR USE AS MODULATORS OF mGluR5 RECEPTORS | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A. (IT) | 2020-11-05 | — | — | US | disclosed |
| EP-3645521-A1 | HETEROCYCLYLMETHYLIDENE DERIVATIVES AND THEIR USE AS MODULATORS OF mGluR5 RECEPTORS | Recordati Industria Chimica E Farmaceutica SPA (IT) | 2020-05-06 | — | — | EP | disclosed |
| WO-2019002571-A1 | HETEROCYCLYLMETHYLIDENE DERIVATIVES AND THEIR USE AS MODULATORS OF mGluR5 RECEPTORS | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2019-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347078-A1 | HETEROCYCLYLMETHYLIDENE DERIVATIVES AND THEIR USE AS MODULATORS OF mGluR5 RECEPTORS | GRM5, GRIK5, GRM2 | GRM5 1/4885CYP3A4 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.